# Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer

Source: https://onco.cc/trials/nct07427394/  
OnCo record `nct07427394` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Camizestrant and Atirmociclib in advanced solid tumours, run by AstraZeneca, now recruiting.

## Summary

Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer is a phase 2 interventional study registered as NCT07427394 by AstraZeneca, with 24 participants planned, started 2026-05-06 and due to reach its primary completion in 2027-12-28. Interventions recorded: Camizestrant and Atirmociclib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07427394
- Phase: 2
- Setting: A Phase IIa, Open-label Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of Camizestrant in Combination With Atirmociclib in Participants With ER-positive, HER2-negative Advanced Breast Cancer (SERENA-1b)
- Sponsor: AstraZeneca
- Enrolled: 24

## Sources

- ClinicalTrials.gov NCT07427394: https://clinicaltrials.gov/study/NCT07427394

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Atirmociclib](https://onco.cc/drugs/atirmociclib/), [Camizestrant](https://onco.cc/drugs/camizestrant/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct07427394.json